SWK Holdings Corporation engages in the specialty finance and asset management businesses.
The company is offering customized financing solutions to a broad range of life-sciences companies, and its business offering clinical development and manufacturing services to pharmaceutical partners, as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform.
Segments
The company's operations comprise two reportable segments: 'F...
SWK Holdings Corporation engages in the specialty finance and asset management businesses.
The company is offering customized financing solutions to a broad range of life-sciences companies, and its business offering clinical development and manufacturing services to pharmaceutical partners, as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform.
Segments
The company's operations comprise two reportable segments: 'Finance Receivables' and 'Pharmaceutical Development'.
The company evaluates and invests in a broad range of healthcare related companies and products with intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, 'life science').
Finance Receivables Segment
The company's Finance Receivables segment strategy is to be a leading healthcare capital provider by offering customized financing solutions to a broad range of life science companies, institutions and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The company's business partners are primarily engaged in selling products that directly or indirectly treat diseases and/or improve the wellness of people or animals, or they receive royalties paid on the sales of such products. For example, the company's biotechnology and pharmaceutical business partners commercialize medicines that treat disease states, whereas the company's life science tools partners sell a wide variety of research instrumentation to help other companies conduct clinical research.
The company continues to identify and review financing and similar opportunities on an ongoing basis with financial solutions that are tailored to the individual needs of the company's business partners. In addition, through the company's wholly-owned subsidiary, SWK Advisors LLC, the company is able to provide non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. SWK Advisors LLC is registered as an investment advisor with the Texas State Securities Board. The company intends to fund transactions through its own working capital and the company's revolving credit facility, as well as by building the company's asset management business by raising additional third-party capital.
The company fills an underserved niche in the sub-$50 million transaction size market.
As of March 14, 2024, and since inception of the strategy, the company and its partners have executed transactions with 55 different parties under the company's specialty finance strategy, funding an aggregate of approximately $779.4 million in various financial products across the life science sector. The company's portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property.
The majority of the company's finance receivables transactions are structured similarly to factoring transactions whereby the company provide capital in exchange for an interest in an existing revenue stream. The company primarily provides capital to companies following the commercialization of a product, although in certain situations the company consider pre-approval financings as well. The existing revenue stream can take several forms, but is most commonly either a royalty derived from the sales of a life science product marketed by a third party, such as a royalty paid to an inventor on the sales of a medicine, or from the commercialization by partner company, such as a medical device company that directly sells its own products. The company's structured debt investments may include warrants or other features, giving the company the potential to realize enhanced returns. Capital that the company provides directly to the company's partners is generally used for growth and general working capital purposes, as well as for acquisitions or recapitalizations in select cases.
Although the company has partnered with investment advisory clients in the past, the company does not have any transactions in which the company has partnered with investment advisory clients. The company may seek to raise discretionary capital from similar investors in the future.
The company sources its investment opportunities through a combination of the company's senior management's proprietary relationships within the industry, outbound business development efforts and inbound inquiries from companies, institutions and inventors interested in learning about the company's capital financing alternatives. The company's investment advisory clients generally do not originate investment opportunities for the company.
Pharmaceutical Development Segment
During 2019, the company commenced its Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. ('Enteris'). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners, as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. The company seeka to generate income by providing customers pharmaceutical development, formulation and manufacturing services, as well as licensing its internally developed intellectual property. With an effective date of January 1, 2024, the company entered into an Option and Asset Purchase Agreement with AptarGroup, Inc. ('Aptar') on March 14, 2024, which granted Aptar an exclusive option to acquire certain of Enteris' assets related to its business of providing good manufacturing practice (GMP) manufacturing and clinical supply services through Phase 1 and 2 to third parties, subject to certain exclusions. Aptar must exercise the option by or before January 1, 2026.
History
SWK Holdings Corporation was founded in 1996. The company was incorporated in 1996 in California and reincorporated in Delaware in 1999.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
